Skip to main content

Advertisement

SpringerLink
Log in

Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 -. Record No. 113622, Hepatocellular carcinoma; [updated 2016 Feb 15, cited February 9, 2017]; [about 24 screens]. Available from http://search.ebscohost.com/login.aspx?direct=true&db=dnh&AN=113622&site=dynamed-live&scope=site. Registration and login required.

  2. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J. 2007;100(9):909–11.

    Article  PubMed  Google Scholar 

  3. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.

    Article  CAS  Google Scholar 

  4. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–72.

    Article  CAS  PubMed  Google Scholar 

  5. Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–76.

    Article  CAS  PubMed  Google Scholar 

  6. Mousa AB. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14(2):40–2.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP. 2010;11(3):283–4.

    PubMed  Google Scholar 

  8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  Google Scholar 

  9. Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5:648–61.

    Article  PubMed  Google Scholar 

  10. Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the American Society of Clinical Oncology Conference: Chicago, IL; 2007.

  11. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–37.

    Article  CAS  PubMed  Google Scholar 

  12. Chou JW, Cheng KS, Huang CW. Sorafenib-induced acute pancreatitis: a case report and review of the literature. Intern Med. 2016;55:623–7.

    Article  CAS  PubMed  Google Scholar 

  13. Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc. 2007;82:521.

    Article  PubMed  Google Scholar 

  14. Kobayashi Y, Kanemitu T, Kamoto A, et al. Painless acute pancreatitis associated with sorafenib treatment: a case report. Med Oncol. 2011;28:463–5.

    Article  PubMed  Google Scholar 

  15. Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. J Oncol Pharm Pract. 2012;19(3):257–60.

    Article  PubMed  Google Scholar 

  16. Olayode A, Kizer R. Acute pancreatitis secondary to sorafenib use. Am J Gastroenterol. 2013;108(1):S262.

    Google Scholar 

  17. Wang HE, Chen CT, Huang HH. Sorafenib-induced acute pancreatitis. J Med Sci. 2014;34:126–8.

    Article  Google Scholar 

  18. Reig M, Forner A, Rimola J, de Lope CR, Ayuso C, Llovet JM, et al. 815 sorafenib for the treatment of advanced hepatocellular carcinoma. Feasibility and safety outside research trials. J Hepatol [Internet]. European Association for the Study of the Liver. 2009;50:Se298. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168827809608175

    Google Scholar 

  19. ECOG performance status: http://ecog-acrin.org/resources/ecog-performance-status

  20. Hameed AM, Lam VWT, Pleass HC. Significant elevations of serum lipase not caused by pancreatitis: a systematic review. HPB. 2015;17(2):99–112.

    Article  PubMed  Google Scholar 

  21. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–76.

    Article  CAS  PubMed  Google Scholar 

  22. Klar E, Messmer K, Warshaw AL, et al. Pancreatic ischaemia in experimental acute pancreatitis: mechanism, significance and therapy. Br J Surg. 1990;77:1205–10.

    Article  CAS  PubMed  Google Scholar 

  23. Ueda T, Takeyama Y, Yasuda T, et al. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J Surg Res. 2006;134:223–30.

    Article  CAS  PubMed  Google Scholar 

  24. Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, et al. Phase I/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer. PLoS One 2016;11(12):1–14.

  25. Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, et al. A case of pancreatic side effects resulting from sorafenib and axitinib treatment of stage IV renal cell carcinoma. Keio J Med. 2015;64(4):62–4.

  26. Péron J, Khenifer S, Potier V, et al. Axitinib-induced acute pancreatitis: a case report. Anti-Cancer Drugs. 2014;25:478–9.

    Article  CAS  PubMed  Google Scholar 

  27. Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP. 2010;11:291–3.

    PubMed  Google Scholar 

  28. Kawakubo K, Hata H, Kawakami H, Kuwatani M, Kawahata S, Kubo K, et al. Pazopanib-induced severe acute pancreatitis. Case Rep Oncol. 2015;8:356–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011;72:294–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

No funding was provided for the publication of this article, and the authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Saba University School of Medicine, The Bottom, Dutch-Caribbean, the Netherlands

    Patrick Twohig & Jaclyn Rivington

  2. MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH, 44109, USA

    Patrick Twohig & Jaclyn Rivington

Authors
  1. Patrick Twohig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaclyn Rivington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Twohig.

Ethics declarations

Consent

Informed consent was obtained from the patient for publication of this case report and any accompanying images.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Twohig, P., Rivington, J. Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature. J Gastrointest Canc 50, 137–142 (2019). https://doi.org/10.1007/s12029-017-9980-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9980-3

Keywords

Search

Navigation